Triamcinolone Acetonide

Verify with FDA CVM →

702 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
702
Total Reports
50
Deaths Reported
710.0%
Death Rate

Active Ingredients

Triamcinolone Acetonide

Administration Routes

UnknownSubcutaneousIntra-ArticularTopicalIntramuscularOralParenteralIntralesionalIntrasynovialAuricular (Otic)

Species Affected

Dog 333
Unknown 223
Horse 87
Cat 52
Human 5
Other Canids 1
Other 1

Most Affected Breeds

Unknown 230
Domestic Shorthair 32
Retriever - Labrador 26
Quarter Horse 25
Terrier - Yorkshire 16
Chihuahua 15
Dachshund (unspecified) 15
Horse (unknown) 14
Crossbred Canine/dog 13
Retriever - Golden 13

Most Reported Reactions

Suspension, Abnormal 121
Vomiting 78
Lethargy (see also Central nervous system depression in 'Neurological') 68
Other abnormal test result NOS 44
Lameness 41
Emesis 41
Precipitate, Sediment 40
Anaphylaxis 29
Product problem 29
Death 27
Behavioural disorder NOS 26
Ataxia 24

Outcome Breakdown

Recovered/Normal
171 (41.1%)
Outcome Unknown
102 (24.5%)
Ongoing
72 (17.3%)
Died
31 (7.5%)
Recovered with Sequela
21 (5.0%)
Euthanized
19 (4.6%)

Data Summary

Metric Value
Total adverse event reports 702
Reports involving death 50
Case-fatality rate (reported events) 710.0%
Distinct species in reports 7
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Triamcinolone Acetonide Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 702 adverse event reports referencing Triamcinolone Acetonide, including 50 reports in which the animal died — a 710.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Triamcinolone Acetonide. Reported administration routes include Unknown, Subcutaneous, Intra-Articular, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Triamcinolone Acetonide reports are Dog (333 reports), Unknown (223 reports), Horse (87 reports), with Dog accounting for the largest share. Within those species, Unknown (230), Domestic Shorthair (32), Retriever - Labrador (26) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Triamcinolone Acetonide are Suspension, Abnormal (121), Vomiting (78), Lethargy (see also Central nervous system depression in 'Neurological') (68), Other abnormal test result NOS (44). Of the 416 reports with a coded outcome, Recovered/Normal is the leading category at 41.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Triamcinolone Acetonide.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial